RayKnowChina Research Map
Shortlist

ShenzhenPeking University Health Science Center

Peking University Shenzhen Hospital

北京大学深圳医院

Listed for 23 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Peking University Shenzhen Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Hepatocellular carcinoma肝细胞癌22 papers led
  3. Stomach cancer胃癌8 papers led
  4. Lung cancer肺癌33 papers led1 open trial led
  5. Breast cancer乳腺癌28 papers led
  6. Glioma胶质瘤7 papers led
  7. Chordoma脊索瘤0 papers led
  8. Osteosarcoma骨肉瘤2 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  10. Neuroblastoma神经母细胞瘤1 paper led
  11. Multiple myeloma多发性骨髓瘤1 paper led
  12. Lymphoma淋巴瘤9 papers led
  13. Beta thalassaemiaβ 地中海贫血1 paper led
  14. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  15. IgG4-related diseaseIgG4相关性疾病2 papers led
  16. Congenital heart disease先天性心脏病3 papers led
  17. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  18. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  19. Fabry disease法布雷病0 papers led
  20. Alport syndromeAlport 综合征2 papers led
  21. IgA nephropathyIgA 肾病1 paper led
  22. Osteogenesis imperfecta成骨不全症1 paper led
  23. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Oesophageal squamous cell carcinoma, Pancreatic cancer, Hepatoblastoma, Retinoblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 1120232024: 0020242025: 112025

8 hospitals in Shenzhen for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06301165

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan

  2. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEBV & screeningRecurrent / metastatic diseaseRadiotherapy technique
Departments in papersPathology / laboratory medicineMedical oncologyENT / head & neck surgeryNeurology

Over half of these papers are lab or animal studies.

Papers it led8
  1. A three-miRNA panel in serum: Serving as a novel diagnostic method for nasopharyngeal carcinoma.2025The International journal of biological markers
  2. Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma.2023Journal of translational medicineFree full text
  3. Identification of DNA aptamers that specifically targets EBV+ nasopharyngeal carcinoma via binding with EphA2/CD98hc complex.2022Biochemical and biophysical research communications
  4. A panel of three serum microRNA can be used as potential diagnostic biomarkers for nasopharyngeal carcinoma.2022Journal of clinical laboratory analysisFree full text
  5. The Highly Expressed IFIT1 in Nasopharyngeal Carcinoma Enhances Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells.2022Molecular biotechnology
  6. Long-term recurrence and brain metastasis of nasopharyngeal carcinoma mimicking cystic radiation encephalopathy relapse: a case report.2021BMC neurologyFree full text
  7. Transcriptomic Analyses Reveal Gene Expression Profiles and Networks in Nasopharyngeal Carcinoma.2021BioMed research internationalFree full text
  8. DVH Prediction for VMAT in NPC with GRU-RNN: An Improved Method by Considering Biological Effects.2021BioMed research internationalFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Study siteStart 2024-04
  2. TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06301165Study sitePhase 2Start 2024-03
  3. To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal CancerStatus unknownNCT05198531Study sitePhase 1/Phase 2Start 2022-01
More papers found outside PubMed (not counted)4
  1. Small Molecule G07 Exhibits Dual Effects on Cell Motility by Enhancing Skin Wound Healing and Inhibiting Nasopharyngeal Carcinoma Metastasis2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. Additional file 1 of Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma2023Figsharedataset
  3. Additional file 3 of Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma2023Figsharedataset
  4. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 22 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
22
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 4420232024: 3320242025: 772025

8 hospitals in Shenzhen for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07500220

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  2. Recruiting
    Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07523529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led22
  1. Membranous Staining of CD10 Is Related to Steatosis Changes in Hepatocellular Carcinoma: An Investigation of CD10 Stainning in Hepatocellular Carcinoma, Focal Nodular Hyperplasia, and Intrahepatic Cholangiocarcinoma.2025Applied immunohistochemistry & molecular morphology : AIMM
  2. High expression of SMPD4 promotes liver cancer and is associated with poor prognosis.2025BMC research notesFree full text
  3. Prognostic implication of six m6A-modulated genes signature in the ferroptosis for hepatocellular carcinoma patients.2025Clinical and experimental medicineFree full text
  4. LONP1 Promotes Hepatocarcinogenesis by Degrading ACO2 to Alleviate Ferroptosis.2025Frontiers in bioscience (Landmark edition)
  5. Deciphering Epigenetic and Post-Translational Modifications in Ferroptosis: A Scientometric and Visualization Study.2025International journal of medical sciencesFree full text
  6. Plasma lipidomic analysis reveals disruption of ether phosphatidylcholine biosynthesis and facilitates early detection of hepatitis B-related hepatocellular carcinoma.2025Lipids in health and diseaseFree full text
  7. ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA.2025Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  8. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.2024Apoptosis : an international journal on programmed cell death
  9. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.2024Frontiers in immunologyFree full text
  10. Targeting ferroptosis in hepatocellular carcinoma.2024Hepatology international
  11. Silencing of TMED5 inhibits proliferation, migration and invasion, and enhances apoptosis of hepatocellular carcinoma cells.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  12. A novel hepatocellular carcinoma-specific mTORC1-related signature for anticipating prognosis and immunotherapy.2023AgingFree full text
  13. Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC.2023International journal of oncologyFree full text
  14. MAT1A Suppression by the CTBP1/HDAC1/HDAC2 Transcriptional Complex Induces Immune Escape and Reduces Ferroptosis in Hepatocellular Carcinoma.2023Laboratory investigation; a journal of technical methods and pathology
  15. MicroRNA-139-5p negatively regulates NME1 expression in hepatocellular carcinoma cells.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  16. LINC02362 attenuates hepatocellular carcinoma progression through the miR-516b-5p/SOSC2 axis.2022AgingFree full text
  17. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.2022BMC cancerFree full text
  18. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.2022BioengineeredFree full text
  19. Objective to identify and verify the regulatory mechanism of DTNBP1 as a prognostic marker for hepatocellular carcinoma.2022Scientific reportsFree full text
  20. Angiotensin II promotes EMT of hepatocellular carcinoma cells through high mobility group protein B1 mediated by E4F1.2021Biochemical and biophysical research communications
  21. Identification of Biomarkers Related to Immune Cell Infiltration in Hepatocellular Carcinoma Using Gene Co-Expression Network.2021Pathology oncology research : PORFree full text
  22. Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α-Fetoprotein.2021The Journal of molecular diagnostics : JMD
Chinese-language papers (not in the count)1
  1. [Research progress on ferroptosis regulation in tumor immunity of hepatocellular carcinoma].2024Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCRecruitingNCT07500220Study sitePhase 1/Phase 2Start 2026-03
  2. Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsRecruitingNCT07523529Study sitePhase 1/Phase 2Start 2026-03
  3. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  4. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 8 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.08%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 2220242025: 112025

7 hospitals in Shenzhen for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07523529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  2. Recruiting
    Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07551362

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChemotherapy & combined treatmentImmunotherapy & targeted drugsImaging & AI
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led8
  1. The IL-17 axis in gastric carcinogenesis: From inflammation to oncogenic transformation.2026Cytokine & growth factor reviews
  2. Single-cell multi-omics analysis reveals the plasticity of isthmus stem cells in gastric carcinogenesis.2025Computers in biology and medicine
  3. PDLIM1 interacts with HK2 to promote gastric cancer progression through enhancing the Warburg effect via Wnt/β-catenin signaling.2024Cell and tissue research
  4. Prognostic value of inflammatory and nutritional indexes among patients with unresectable advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy-a retrospective study.2024PeerJFree full text
  5. FTO Promotes the Stemness of Gastric Cancer Cells.2023DNA and cell biology
  6. Immune activity score to assess the prognosis, immunotherapy and chemotherapy response in gastric cancer and experimental validation.2023PeerJFree full text
  7. HIF in Gastric Cancer: Regulation and Therapeutic Target.2022Molecules (Basel, Switzerland)Free full text
  8. Mutations in ALK and TSC1 in a gastrointestinal stromal tumor: a case report.2021BMC surgeryFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsRecruitingNCT07523529Study sitePhase 1/Phase 2Start 2026-03
  2. Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ CancerRecruitingNCT07551362Study sitePhase 1/Phase 2Start 2026-03
  3. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  4. Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer TrialStatus unknownNCT04744649Study sitePhase 2Start 2021-03
  5. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  6. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  7. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerStatus unknownNCT04139135Study sitePhase 3Start 2019-12
  8. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  9. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 33 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
33
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 6620212022: 5520222023: 6620232024: 6620242025: 992025

5 hospitals in Shenzhen for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07374614

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Shenzhen HospitalShenzhen

  2. Recruiting
    A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07361497

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shantou, Shenzhen, Suzhou, Taiyuan, Taizhou, Xi'an, Zhengzhou

  3. Recruiting
    Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07467863

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  4. Recruiting
    Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07480213

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  5. Recruiting
    Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07641023

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  6. Recruiting
    Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07744256

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  7. Recruiting
    A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07375316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Shantou, Shenzhen

  8. Recruiting
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06095583

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou

  9. Not yet recruiting
    Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT06709274

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Chengdu, Foshan, Guangzhou, Nanjing, Nantong, Shenzhen, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineMedical oncologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led33
  1. Unlocking Spondin-1 and Spondin-2 as Ultrasound-Responsive Biomarkers in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: Diagnostic and Therapeutic Perspectives.2026Cancer biotherapy & radiopharmaceuticals
  2. A Nomogram for the Prediction of Invasiveness in Invasive Pulmonary Adenocarcinoma on the Basis of Multimodal PET/CT Parameters.2025Academic radiology
  3. Metabolic characteristics of benign and malignant pulmonary nodules and establishment of invasive lung adenocarcinoma model by high-resolution mass spectrometry.2025BMC cancerFree full text
  4. Incidence and risk factors of postoperative delirium in patients undergoing elective lung cancer surgery : a retrospective study using the national inpatient sample database.2025BMC surgeryFree full text
  5. Transcriptome profiling of tumor-infiltrating lymphocyte-mediated cytotoxicity against patient-derived lung cancer organoids.2025Communications biologyFree full text
  6. TFAP2A Promotes Cell Progression and Suppresses Ferroptosis in Lung Adenocarcinoma via Activating Transcription of CST1.2025Journal of biochemical and molecular toxicology
  7. LINC00892 as a Prognostic Biomarker in Lung Adenocarcinoma: Role in Immune Infiltration and EMT Suppression.2025Journal of immunology researchFree full text
  8. Synthesis of a novel specific nectin-4 tumor-targeted peptide optical molecular probe and its preliminary study in lung cancer.2025Scientific reportsFree full text
  9. CALML3-AS1 enhances malignancies and stemness of small cell lung cancer cells through interacting with DAXX protein and promoting GLUT4-mediated aerobic glycolysis.2025Toxicology and applied pharmacology
  10. Bronchial salivary gland-type mucinous adenocarcinoma harboring a GNAS mutation: a novel lung cancer entity? A case report.2025Virchows Archiv : an international journal of pathologyFree full text
  11. USP7 deubiquitinates KRAS and promotes non-small cell lung cancer.2024Cell reports
  12. A Comprehensive Exploration of Metabolism and Tumor Microenvironment and Immunotherapy Response: Evidence From Large Populations in Non-small Cell Lung Cancer.2024Current cancer drug targets
  13. Integrative analysis of anoikis-related genes prognostic signature with immunotherapy and identification of CDKN3 as a key oncogene in lung adenocarcinoma.2024International immunopharmacology
  14. Unveiling the Enigmatic Role of SLC35F3 in Lung Adenocarcinoma.2024The clinical respiratory journalFree full text
  15. Comparison of Efficacy and Safety of Different Guided Technologies Combined With Ultrathin Bronchoscopic Biopsy for Peripheral Pulmonary Lesions.2024The clinical respiratory journalFree full text
  16. Circ_0020123 promotes non-small cell lung cancer progression via miR-146a-5p mediated regulation of EIF4G2 expression.2024Thoracic cancerFree full text
  17. CircLIFR Inhibits Non-small Cell Lung Cancer Progression by Acting as a miR-429 Sponge to Enhance CELF2 Expression.2023Biochemical genetics
  18. Identification of molecular subgroups and establishment of risk model based on the response to oxidative stress to predict overall survival of patients with lung adenocarcinoma.2023European journal of medical researchFree full text
  19. Characteristics of Metastatic and Nonmetastatic Pulmonary Sclerosing Pneumocytomas: A Clinicopathological Study of 68 Cases and 15 Reported Metastatic Cases.2023Laboratory investigation; a journal of technical methods and pathology
  20. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.2023Respiratory researchFree full text
  21. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.2023Respiratory researchFree full text
  22. Bronchoalveolar Lavage as Potential Diagnostic Specimens to Genetic Testing in Advanced Nonsmall Cell Lung Cancer.2023Technology in cancer research & treatmentFree full text
  23. Circular RNA circ_0007841 participates in progression of nonsmall cell lung cancer via miR-199a-5p/SphK2 axis.2022Anti-cancer drugs
  24. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research.2022Anti-cancer drugsFree full text
  25. LINC02126 is a potential diagnostic, prognostic and immunotherapeutic target for lung adenocarcinoma.2022BMC pulmonary medicineFree full text
  26. Circular RNA circ_0067741 regulates the Hippo/YAP pathway to suppress lung adenocarcinoma progression by targeting microRNA-183-5p.2022BioengineeredFree full text
  27. CHEK1: a hub gene related to poor prognosis for lung adenocarcinoma.2022Biomarkers in medicine
  28. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.2021Acta biochimica et biophysica Sinica
  29. Risk factors and survival outcomes of laryngeal squamous cell carcinoma patients with lung metastasis: A population-based study.2021Auris, nasus, larynx
  30. Tadalafil Reverses the Effect of Three-Dimensional Cell Culture System on Stem Cell Features in A549 and SK-MES-1.2021DNA and cell biology
  31. Exosome-derived miR-2682-5p suppresses cell viability and migration by HDAC1-silence-mediated upregulation of ADH1A in non-small cell lung cancer.2021Human & experimental toxicology
  32. Demethyleneberberine induces cell cycle arrest and cellular senescence of NSCLC cells via c-Myc/HIF-1α pathway.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
  33. Postoperative transient elevation of serum cancer antigen 125 in non-small cell lung cancer patients.2021Revista da Associacao Medica Brasileira (1992)
All its trials on ClinicalTrials.gov, any status17
  1. Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After LorlatinibRecruitingNCT07374614Lead sponsorStart 2026-01
  2. Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)RecruitingNCT07744256Study sitePhase 1/Phase 2Start 2026-03
  3. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)RecruitingNCT07361497Study sitePhase 3Start 2026-03
  4. Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLCRecruitingNCT07641023Study sitePhase 1/Phase 2Start 2026-03
  5. Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)RecruitingNCT07480213Study sitePhase 1/Phase 2Start 2026-02
  6. Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLCRecruitingNCT07467863Study sitePhase 1/Phase 2Start 2026-02
  7. A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyRecruitingNCT07375316Study sitePhase 2Start 2025-12
  8. Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNCT06709274Study siteN/AStart 2024-11
  9. Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)RecruitingNCT06095583Study sitePhase 3Start 2023-11
  10. A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerActive, not recruitingNCT05353257Study sitePhase 3Start 2022-05
  11. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Study sitePhase 2Start 2022-06
  12. Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Study sitePhase 3Start 2020-07
  13. A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Study sitePhase 3Start 2020-01
  14. Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Study sitePhase 3Start 2020-12
  15. Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKICompletedNCT03924050Study sitePhase 3Start 2019-05
  16. mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung CancerCompletedNCT03196986Study sitePhase 3Start 2017-08
  17. Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaStatus unknownNCT02103257Study sitePhase 4Start 2014-03

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 28 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
28
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 4420212022: 4420222023: 7720232024: 6620242025: 662025

7 hospitals in Shenzhen for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07486089

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  2. Recruiting
    Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07510802

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  3. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

  4. Recruiting
    Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07095023

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Shantou, Shenzhen, Wenzhou

  5. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  6. Not yet recruiting
    Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07657169

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 3 listed hospitals as study sitesGuangzhou, Jinan, Qingdao, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineMedical oncology
Papers it led28
  1. A dual-responsive metal-polyphenol nanomedicine based on targeting LAT1 via levodopa and ROS amplification for precise treatment of breast cancer.2026Free radical biology & medicine
  2. Predicting axillary lymph node metastasis in breast cancer patients using CNN-GCN on DCE-MRI: a multicenter study.2025BMC medical imagingFree full text
  3. A case report of breast abscess caused by Peptoniphilus harei after endoscopic breast-conserving surgery and radiotherapy for breast cancer and literature review.2025BMC women's healthFree full text
  4. Spinal Metastasis Pain Surveillance: A Comprehensive Imaging-Based Tool Design for Evaluating Metastatic Burden and Guiding Therapeutic Strategies.2025International journal of medical sciencesFree full text
  5. Performance of ChatGPT-4o, Claude 3 Opus, and DeepSeek-R1 in BI-RADS Category 4 Classification and Malignancy Prediction From Mammography Reports: Retrospective Diagnostic Study.2025JMIR medical informaticsFree full text
  6. Development and Validation of a Deep Learning System to Differentiate HER2-Zero, HER2-Low, and HER2-Positive Breast Cancer Based on Dynamic Contrast-Enhanced MRI.2025Journal of magnetic resonance imaging : JMRI
  7. The effect of tailored nursing interventions based on the IKAP model on the discharge readiness of the spouses or children of breast cancer patients: a randomized controlled trial.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCTFree full text
  8. Liensinine diperchlorate and artemisitene synergistically attenuate breast cancer progression through suppressing PI3K-AKT signaling and their efficiency in breast cancer patient-derived organoids.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. Simultaneous Targeting of NQO1 and SOD1 Eradicates Breast Cancer Stem Cells via Mitochondrial Futile Redox Cycling.2024Cancer researchFree full text
  10. The diagnostic performance of T1 mapping in the assessment of breast lesions: A preliminary study.2024European journal of radiology
  11. Non-mass-like breast intraductal carcinoma detected by Micro-Flow imaging and elastography.2024Medical ultrasonography
  12. Effect of yoga on cancer-related fatigue in patients with breast cancer: A systematic review and meta-analysis.2024MedicineFree full text
  13. Artemisitene induces apoptosis of breast cancer cells by targeting FDFT1 and inhibits the growth of breast cancer patient-derived organoids.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  14. NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1.2023Cancer scienceFree full text
  15. Fbxo22 inhibits metastasis in triple-negative breast cancer through ubiquitin modification of KDM5A and regulation of H3K4me3 demethylation.2023Cell biology and toxicologyFree full text
  16. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.2023Cellular signalling
  17. Leveraging senescence-oxidative stress co-relation to predict prognosis and drug sensitivity in breast invasive carcinoma.2023Frontiers in endocrinologyFree full text
  18. Prognosis stratification of patients with breast invasive carcinoma based on cysteine metabolism-disulfidptosis affinity.2023Journal of cancer research and clinical oncologyFree full text
  19. LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling.2023OncogeneFree full text
  20. HLA-DQA1 expression is associated with prognosis and predictable with radiomics in breast cancer.2023Radiation oncology (London, England)Free full text
  21. Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on contrast-enhanced spectral mammography.2022European radiology
  22. Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine.2022International journal of nanomedicineFree full text
  23. Advanced diagnostic imaging of sentinel lymph node in early stage breast cancer.2022Journal of clinical ultrasound : JCUFree full text
  24. Structure-Based Design, Optimization, and Evaluation of Potent Stabilized Peptide Inhibitors Disrupting MTDH and SND1 Interaction.2022Journal of medicinal chemistry
  25. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers.2021ACS synthetic biology
  26. CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.2021BioMed research internationalFree full text
  27. Breast invasive ductal carcinoma diagnosis with a three-miRNA panel in serum.2021Biomarkers in medicine
  28. Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,578 patients.2021Breast (Edinburgh, Scotland)Free full text
All its trials on ClinicalTrials.gov, any status11
  1. Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the BreastNot yet recruitingNCT07657169Study siteN/AStart 2026-10
  2. Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)RecruitingNCT07486089Study sitePhase 1/Phase 2Start 2026-02
  3. Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCRecruitingNCT07510802Study sitePhase 1/Phase 2Start 2026-02
  4. TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerRecruitingNCT07047365Study sitePhase 3Start 2025-07
  5. Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNCT07095023Study siteN/AStart 2025-08
  6. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationRecruitingNCT05696626Study sitePhase 3Start 2023-10
  7. To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerActive, not recruitingNCT05365178Study sitePhase 3Start 2022-07
  8. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)Active, not recruitingNCT04895358Study sitePhase 3Start 2021-06
  9. The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast CancerStatus unknownNCT04185649Study sitePhase 3Start 2018-07
  10. Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast CancerSuspendedNCT02897050Study sitePhase 2Start 2016-09
  11. Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast CancerCompletedNCT02482753Study sitePhase 3Start 2015-07

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 7 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.1%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 2220242025: 112025

4 hospitals in Shenzhen for glioma187 hospitals in China for glioma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glioma
    Phase
    Phase 1
    Started
    2026-02
    Posted
    Registry
    NCT07480941

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  2. Recruiting
    Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07551336

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicinePathology / laboratory medicineNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Shenzhen for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

20 hospitals in Shenzhen for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Shenzhen for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

10 hospitals in Shenzhen for neuroblastoma321 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07502287

    Age 12 months to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 1 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.06%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution

5 hospitals in Shenzhen for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  3. Recruiting
    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07523555

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  4. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Posted
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  5. Recruiting
    BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
    Phase
    Phase 1
    Started
    2019-07
    Posted
    Registry
    NCT04162353

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBispecific & antibody drugs
Departments in papersPathology / laboratory medicine
Papers it led1
  1. Rapid identification and quantification of residual daratumumab in multiple myeloma patients by MALDI - TOF mass spectrometry.2026Clinica chimica acta; international journal of clinical chemistry
All its trials on ClinicalTrials.gov, any status9
  1. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  2. Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Study sitePhase 1/Phase 2Start 2026-03
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  5. BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid LymphomaRecruitingNCT04162353Study sitePhase 1Start 2019-07
  6. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  7. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  8. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  9. BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple MyelomaStatus unknownNCT04156269Study siteEarly phase 1Start 2018-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 9 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 1120242025: 222025

5 hospitals in Shenzhen for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07523555

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  2. Recruiting
    BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
    Phase
    Phase 1
    Started
    2019-07
    Posted
    Registry
    NCT04162353

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led9
  1. BDA-366 inhibits extra-nodal natural killer/T-cell lymphoma by inducing mitochondria damage through NF-κB pathway.2026Biochemical pharmacology
  2. Fucoidan potentiates CAR NK cell-mediated antitumor efficacy against non-Hodgkin lymphoma via NRF2.2026Free radical biology & medicine
  3. Case report of non-gene editing CD7 CAR T cell therapy in CD7+ Sézary syndrome: preclinical validation and first-in-human use.2025Frontiers in immunologyFree full text
  4. BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies.2025Protein & cellFree full text
  5. Indolent T-Cell/Natural Killer-Cell Lymphomas/Lymphoproliferative Disorders of the Gastrointestinal Tract-What Have We Learned in the Last Decade?2024Laboratory investigation; a journal of technical methods and pathology
  6. Primary extranodal soft tissue Lennert lymphoma (lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified): a case report and review of the literature.2023Diagnostic pathologyFree full text
  7. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.2022Blood
  8. Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells.2022Frontiers in immunologyFree full text
  9. Hsa-miR-372-5p regulates the NIMA related kinase 7 and IL-1β release in NK/T-cell lymphoma.2021Leukemia & lymphoma
All its trials on ClinicalTrials.gov, any status10
  1. Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Study sitePhase 1/Phase 2Start 2026-03
  2. BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid LymphomaRecruitingNCT04162353Study sitePhase 1Start 2019-07
  3. A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaStatus unknownNCT05234684Study sitePhase 3Start 2022-11
  4. A Study of Brentuximab Vedotin in Adults With CD30-positive LymphomaCompletedNCT04837222Study siteStart 2021-06
  5. Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell MalignancesStatus unknownNCT04934774Study sitePhase 1Start 2020-12
  6. Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell MalignanciesStatus unknownNCT04594135Study sitePhase 1Start 2020-12
  7. Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabCompletedNCT04282018Study sitePhase 1/Phase 2Start 2020-04
  8. CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell MalignanciesStatus unknownNCT04162340Study sitePhase 1Start 2019-07
  9. CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell MalignanciesStatus unknownNCT04156178Study siteEarly phase 1Start 2018-08
  10. CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell MalignanciesStatus unknownNCT04156243Study siteEarly phase 1Start 2018-02

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Shenzhen for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led1
  1. Mutational spectrum of HBD gene in the Chinese population: Description of 36 mutations including 11 novel variants.2023International journal of laboratory hematology
Chinese-language papers (not in the count)1
  1. [Research progress on differential diagnosis of thalassemia trait and iron deficiency anemia by blood erythrocyte parameters].2024Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Shenzhen for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Shenzhen for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesKidney, retroperitoneum & vesselsDiagnosis & look-alikes
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 3 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025

5 hospitals in Shenzhen for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Shenzhen for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Ibrutinib Delays ALS Installation and Increases Survival of SOD1G93A Mice by Modulating PI3K/mTOR/Akt Signaling.2023Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Shenzhen for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shenzhen for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Chinese-language papers (not in the count)1
  1. [Clinical analysis of 10 patients with Fabry disease].2024Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 2 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 3.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

3 hospitals in Shenzhen for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

10 hospitals in Shenzhen for IgA nephropathy300 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led1
  1. Serum human epididymis protein 4 is associated with disease severity in patients with IgA nephropathy.2024Clinical biochemistry
All its trials on ClinicalTrials.gov, any status5
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  4. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  5. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Shenzhen for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Shenzhen for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

北京大学深圳医院

Peking University Shenzhen Hospital

深圳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Peking University Shenzhen Graduate School; Shenzhen Hospital; Shenzhen Hospital of Peking University; Shenzhen Hospital of Peking Univeristy; Peking University shenzhen hospital; Shenzhen Central Hospital

Suggest a correctionDownload the data